These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35855239)

  • 41. Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells.
    Li Q; Feng Y; Xue Y; Zhan X; Fu Y; Gui G; Zhou W; Richard JP; Taga A; Li P; Mao X; Maragakis NJ; Ying M
    Mol Neurodegener; 2022 Jan; 17(1):8. PubMed ID: 35012575
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evidence-Based Research Strategy of Traditional Chinese Medicine for Amyotrophic Lateral Sclerosis.
    Pan H; Wang H; Tao Y; Yuan J; Xu S; Ni J; Huang M; Wu X; Liu T
    Evid Based Complement Alternat Med; 2021; 2021():3402753. PubMed ID: 34512775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population.
    Tomar S; Gupta S; Singal A; Soni R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443425
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Riluzole for the treatment of amyotrophic lateral sclerosis.
    Saitoh Y; Takahashi Y
    Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Amyotrophic lateral sclerosis with respiratory failure and dysautonomia: a case report.
    Chapagain S; Khati N; Lama R; Karki R; Aryal R; Pangyani B; Koirala A
    Ann Med Surg (Lond); 2023 Jul; 85(7):3623-3625. PubMed ID: 37427180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug.
    Ortiz JF; Khan SA; Salem A; Lin Z; Iqbal Z; Jahan N
    Cureus; 2020 Oct; 12(10):e10818. PubMed ID: 33173626
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study.
    Park JM; Park D; Kim HJ; Park JS
    BMC Neurol; 2022 Jul; 22(1):260. PubMed ID: 35836136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Familial Amyotrophic Lateral Sclerosis].
    Suzuki N; Nishiyama A; Kato M; Warita H; Aoki M
    Brain Nerve; 2019 Nov; 71(11):1169-1181. PubMed ID: 31722303
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis.
    Cho H; Shukla S
    Pharmaceuticals (Basel); 2020 Dec; 14(1):. PubMed ID: 33396271
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone.
    Han HJ; Shin HY; Choi YC; Kim SM; Kim SW
    Redox Rep; 2022 Dec; 27(1):79-84. PubMed ID: 35296219
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Small molecules targeting different cellular pathologies for the treatment of amyotrophic lateral sclerosis.
    Elmansy MF; Reidl CT; Rahaman M; Özdinler PH; Silverman RB
    Med Res Rev; 2023 Nov; 43(6):2260-2302. PubMed ID: 37243319
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis.
    Sawada H
    Expert Opin Pharmacother; 2017 May; 18(7):735-738. PubMed ID: 28406335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disease-modifying therapies in amyotrophic lateral sclerosis.
    Chiò A; Mazzini L; Mora G
    Neuropharmacology; 2020 May; 167():107986. PubMed ID: 32062193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
    Petrov D; Mansfield C; Moussy A; Hermine O
    Front Aging Neurosci; 2017; 9():68. PubMed ID: 28382000
    [TBL] [Abstract][Full Text] [Related]  

  • 55. NU-9 improves health of hSOD1
    Genç B; Gautam M; Helmold BR; Koçak N; Günay A; Goshu GM; Silverman RB; Hande Ozdinler P
    Sci Rep; 2022 Mar; 12(1):5383. PubMed ID: 35354901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Amyotrophic Lateral Sclerosis: An Update for 2018.
    Oskarsson B; Gendron TF; Staff NP
    Mayo Clin Proc; 2018 Nov; 93(11):1617-1628. PubMed ID: 30401437
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overview of stem cells therapy in amyotrophic lateral sclerosis.
    Je G; Keyhanian K; Ghasemi M
    Neurol Res; 2021 Aug; 43(8):616-632. PubMed ID: 33632084
    [No Abstract]   [Full Text] [Related]  

  • 59. Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials.
    Barp A; Gerardi F; Lizio A; Sansone VA; Lunetta C
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):145-164. PubMed ID: 32456491
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse.
    Ikeda K; Iwasaki Y
    PLoS One; 2015; 10(10):e0140316. PubMed ID: 26469273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.